SG Americas Securities LLC Acquires 58,496 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

SG Americas Securities LLC boosted its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 137.6% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 100,993 shares of the biopharmaceutical company’s stock after purchasing an additional 58,496 shares during the quarter. SG Americas Securities LLC’s holdings in Amicus Therapeutics were worth $824,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. raised its position in shares of Amicus Therapeutics by 1.6% in the 4th quarter. Vanguard Group Inc. now owns 29,258,963 shares of the biopharmaceutical company’s stock valued at $275,619,000 after purchasing an additional 458,143 shares during the last quarter. Wellington Management Group LLP boosted its holdings in Amicus Therapeutics by 18.8% during the fourth quarter. Wellington Management Group LLP now owns 28,461,994 shares of the biopharmaceutical company’s stock worth $268,112,000 after buying an additional 4,497,950 shares in the last quarter. Nuveen Asset Management LLC grew its position in shares of Amicus Therapeutics by 4.4% during the 4th quarter. Nuveen Asset Management LLC now owns 3,807,420 shares of the biopharmaceutical company’s stock valued at $35,866,000 after acquiring an additional 159,139 shares during the period. Northern Trust Corp grew its holdings in Amicus Therapeutics by 5.9% in the fourth quarter. Northern Trust Corp now owns 3,371,639 shares of the biopharmaceutical company’s stock valued at $31,761,000 after purchasing an additional 187,652 shares during the period. Finally, Vestal Point Capital LP purchased a new stake in Amicus Therapeutics in the 4th quarter worth $31,557,000.

Analyst Upgrades and Downgrades

FOLD has been the topic of several research reports. UBS Group raised their price target on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Friday, May 2nd. Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. Wall Street Zen cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, May 5th. The Goldman Sachs Group dropped their price target on Amicus Therapeutics from $12.00 to $9.00 and set a “neutral” rating on the stock in a research note on Friday, May 2nd. Finally, Wells Fargo & Company lowered their target price on Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating on the stock in a research note on Thursday, February 20th. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Amicus Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $16.22.

Amicus Therapeutics Price Performance

Shares of NASDAQ:FOLD opened at $5.73 on Friday. Amicus Therapeutics, Inc. has a 12 month low of $5.72 and a 12 month high of $12.65. The stock has a market cap of $1.76 billion, a price-to-earnings ratio of -63.66 and a beta of 0.54. The stock’s 50 day moving average price is $6.40 and its 200 day moving average price is $8.21. The company has a debt-to-equity ratio of 2.02, a current ratio of 3.34 and a quick ratio of 2.47.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.